$NGVT

Fisher Ryan C. sold $200K of NGVT

Fisher Ryan C. (SVP, Gen. Counsel & Secretary) sold 2,709 shares of Ingevity Corp (NGVT) at an average of $73.72 ($73.67–$73.76, $0.20M total) across 2 trades on 2026-08-03.

Original reporting
SEC EDGAR · Fisher Ryan C.
Published Aug 4, 2026, 9:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NGVT
Neutral
medium confidence
Mentioned
$NGVT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NGVTNeutralLow
01

Why it matters

A named officer sold 2,709 shares at roughly $73.67 to $73.76, totaling about $199.7K, with holdings after the sale of 15,722 shares.

02

Market read

Traders may note the insider sale for sentiment, but there is no new operational or financial information.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the article lacks any accompanying narrative or follow-on buying.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04 after-hours; transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Ingevity (NGVT).

Company-level read

Ticker impact

$NGVTNeutralMedium confidence
Context

Ingevity insider Ryan Fisher sold about $199.7K of NGVT shares via an open-market sale reported on SEC Form 4.

Expected impact

Likely minimal near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing provides transaction size, price range, and role, but no earnings, guidance, deal, or regulatory catalyst. Insider sales are common and often not predictive without additional context.

Market effects

No clear sector read-through from a single, small insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as caution.

Key entities

  • Ingevity Corp

    Company whose insider transaction is disclosed on SEC Form 4.

  • Ryan C. Fisher

    SVP, General Counsel & Secretary who executed the open-market sale.

Related articles

$NGVTMedAI 8/10

Ingevity (NGVT) Q2 2026 Earnings Call Transcript

Ingevity (NGVT) held its Q2 2026 earnings call. Net sales were $314 million, down 5% on reported basis due to the Road Markings divestiture. Adjusted EBITDA rose 14% to $115 million, with margin at 36.6%. Adjusted EPS was $1.74. Free cash flow was $89 million. Full-year guidance for EBITDA and EPS was raised.

$NGVTMedAI 8/10

Ingevity Q2 Earnings Call Highlights

Ingevity (NYSE:NGVT) reported Q2 cash flow excluding a litigation settlement of about $89M, or $2.52/share, with capex near $10M. Performance Materials sales rose 4% to $161M, with segment EBITDA up 6% to $86M and margin to 53.6%. The company raised 2026 outlook to adjusted EBITDA $380M-$400M and EPS $5.00-$5.45, plus free cash flow $220M-$245M.

$NGVTMed

Ingevity Corp (NGVT): Results of Operations and Financial Condition

Ingevity Corp (NGVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99106302026.htm EX-99.1 Document Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Ingevity reports second quarter 2026 financial results Second Quarter 2026 Results and Recent Highlights: • Net sales of $31